NovaBridge Biosciences is the renamed predecessor platform after a China exit, now a Rockville-based foreign private issuer whose equity trades as if the pipeline is nearly free. The investment debate is whether two mid-stage programs, a Claudin-directed gastric bispecific and a dual-pathway retinal biologic, deserve more than a cash-floor multiple after a year of regulatory and clinical progress. Liquidity of about $216 million sits against a mid-September capitalization near $185 million. That gap is either a gift if randomized data hold or a fair discount if open-label results fade.
The load-bearing oncology print is the January dose-expansion package for givastomig, the Claudin by four-one-BB bispecific. Confirmed responses reached 77% at the lower expansion dose. That rate came from 52 evaluable patients, with long median progression-free survival in the smaller subset. Those figures sit well above historical immunochemotherapy baselines in first-line gastric cancer, which is why the agency later granted Fast Track and aligned on a possible accelerated path. The counterargument is sample size and the absence of a randomized control. Open-label combinations with nivolumab and FOLFOX can flatter response rates that later compress.
First-half results show the cost of that ambition. Research spending more than tripled and administrative costs jumped on share awards plus a one-time write-off of the abandoned Hong Kong listing. Operating cash outflow ran at a $33 million half-year clip. That clip is still compatible with management's claim that cash funds the planned registrational interim. The question the next year resolves is whether a registrational gastric study actually opens and whether the retinal program enters a controlled mid-stage trial before burn steps up.